Explore the words cloud of the LEPVORS project. It provides you a very rough idea of what is the project "LEPVORS" about.
The following table provides information about the project.
Coordinator |
SCHWEIZERISCHES TROPEN- UND PUBLIC HEALTH-INSTITUT
Organization address contact info |
Coordinator Country | Switzerland [CH] |
Total cost | 153˙916 € |
EC max contribution | 153˙916 € (100%) |
Programme |
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility) |
Code Call | H2020-MSCA-IF-2018 |
Funding Scheme | MSCA-IF-GF |
Starting year | 2019 |
Duration (year-month-day) | from 2019-05-01 to 2022-01-31 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | SCHWEIZERISCHES TROPEN- UND PUBLIC HEALTH-INSTITUT | CH (Basel) | coordinator | 153˙916.00 |
2 | BOARD OF GOVERNORS OF THE COLORADO STATE UNIVERSITY SYSTEM | US (FORT COLLINS) | partner | 0.00 |
Leprosy is a multiform infection caused by Mycobacterium leprae, an uncultivable bacLeprosy is a slow and chronic infection caused by Mycobacterium leprae. Recent advances in the next generation sequencing offer a new possibility to study the physiopathology of M. leprae, an uncultivable bacteria on anexic media. In 2018, the comparative analysis of 154 M. leprae genomes from 25 countries identified three hypermutated genes including two (ribD and fadD9) probably associated with drug-resistant and the most mutated one being ml0411 with a potential role in host adaptation. In a mycobacterial species, like M. leprae, with such a reduced number of coding genes, it is reasonable to assume that this high rate of mutations probably led to the modification of essential biological functions. In addition, the recent development of more efficient molecular tools can now help to obtain the whole genome sequencing of the strain from the low representative forms of the disease. This could help to identify more of these highly mutated genes and establish a link between the pathogen genetic and the clinical disease outcome. This project proposes to functionally characterize some of the mutations identified but also to identify new candidates which could be linked with differences in host phenotype. The study has three specific aims: Specific aim 1 will focus on potential new genes involved in M. leprae drug resistance. Using surrogate mycobacteria such as M. tuberculosis and M. haemophilum, we will test the drug susceptibility of mutated strains in fadD9 and ribD compared to wild-type strains. In specific aim 2, we will investigate the role of ml0411 and mutated version on the host innate immune response modulation In specific aim 3, we will focus on the whole genome sequencing of M. leprae strain from the less represented clinical form of leprosy, the tuberculoid pole to identify new genetic differences in the bacteria which could be associated with different host phenotypes.
year | authors and title | journal | last update |
---|---|---|---|
2020 |
Katharina Röltgen, Gerd Pluschke, John Stewart Spencer, Patrick Joseph Brennan, Charlotte Avanzi The immunology of other mycobacteria: M. ulcerans, M. leprae published pages: , ISSN: 1863-2297, DOI: 10.1007/s00281-020-00790-4 |
Seminars in Immunopathology | 2020-03-05 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LEPVORS" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "LEPVORS" are provided by the European Opendata Portal: CORDIS opendata.